Volume 31, Number 5—May 2025
Synopsis
Outbreak of Marburg Virus Disease, Equatorial Guinea, 2023
Stephanie Ngai
, Egmond Samir Evers, Angela Katherine Lao Seoane, George Ameh, Julienne N. Anoko, Céline Barnadas, Mary J. Choi, Janet Diaz, Luca Fontana, Pierre Formenty, Ingrid Hammermeister Nezu, Frédérique Jacquerioz, John Klena, Henry Laurenson-Schafer, Olivier le Polain de Waroux, Anaïs Legand, Raquel Medialdea Carrera, Tatiana Metcalf, Joel Montgomery, Silvia Morreale, María E. Negrón, Justino Obama Nvé, Mitoha Ondo’o Ayekaba, Boris I. Pavlin, Trevor Shoemaker, Yaimara Torres Hernandez, Mabel Varona Venta, Emily Z. Gutierrez, Florentino Abaga Ondo Ndoho, and on behalf of the Marburg Virus Disease Outbreak Response Working Group1
, Egmond Samir Evers, Angela Katherine Lao Seoane, George Ameh, Julienne N. Anoko, Céline Barnadas, Mary J. Choi, Janet Diaz, Luca Fontana, Pierre Formenty, Ingrid Hammermeister Nezu, Frédérique Jacquerioz, John Klena, Henry Laurenson-Schafer, Olivier le Polain de Waroux, Anaïs Legand, Raquel Medialdea Carrera, Tatiana Metcalf, Joel Montgomery, Silvia Morreale, María E. Negrón, Justino Obama Nvé, Mitoha Ondo’o Ayekaba, Boris I. Pavlin, Trevor Shoemaker, Yaimara Torres Hernandez, Mabel Varona Venta, Emily Z. Gutierrez, Florentino Abaga Ondo Ndoho, and on behalf of the Marburg Virus Disease Outbreak Response Working Group1
Table
Reported symptoms among case-patients with Marburg virus disease, Equatorial Guinea, January–April 2023*
| Symptom | Death, confirmed | Survivor, confirmed | Total, confirmed | Total, probable | Total, confirmed and probable |
|---|---|---|---|---|---|
| Fever | 12/12 (100.0) | 4/4 (100.0) | 16/16 (100.0) | 16/18 (88.9) | 32/34 (94.1) |
| Abdominal pain | 3/4 (75.0) | 3/3 (100.0) | 6/7 (85.7) | ND | 6/7 (85.7) |
| Fatigue | 8/12 (66.7) | 4/4 (100.0) | 12/16 (75.0) | 10/18 (55.6) | 22/34 (64.7) |
| Nausea/vomiting | 8/11 (72.7) | 2/4 (50.0) | 10/15 (66.7) | 16/18 (88.9) | 26/33 (78.8) |
| Anorexia/loss of appetite | 5/10 (50.0) | 4/4 (100.0) | 9/14 (64.3) | 2/4 (50.0) | 11/18 (61.1) |
| Convulsions | 5/5 (100.0) | 0/3 (0.0) | 5/8 (62.5) | ND | 5/8 (62.5) |
| Rash | 0/2 (0.0) | 3/3 (100.0) | 3/5 (60.0) | ND | 3/5 (60.0) |
| Any hemorrhagic sign | 8/12 (66.7) | 0/4 (0.0) | 8/16 (50.0) | 13/21 (61.9) | 21/37 (56.8) |
| Joint or muscle pain | 3/10 (30.0) | 3/4 (75.0) | 6/14 (42.9) | 7/18 (38.9) | 13/32 (40.6) |
| Headache | 4/9 (44.4) | 1/4 (25.0) | 5/13 (38.5) | 2/5 (40.0) | 7/18 (38.9) |
| Conjunctivitis | 2/3 (66.7) | 0/3 (0.0) | 2/6 (33.3) | ND | 2/6 (33.3) |
| Hematemesis | 4/11 (36.4) | 0/4 (0.0) | 4/15 (26.7) | 13/18 (72.2) | 17/33 (51.5) |
| Difficulty breathing | 3/11 (27.3) | 0/4 (0.0) | 3/15 (20.0) | 2/18 (11.1) | 5/33 (15.2) |
| Difficulty swallowing | 0/9 (0.0) | 2/4 (50.0) | 2/13 (15.4) | 0/4 (0.0) | 2/17 (11.8) |
| Bloody diarrhea | 2/9 (22.2) | 0/4 (0.0) | 2/13 (15.4) | 12/18 (66.7) | 14/31 (45.2) |
| Diarrhea | 2/11 (18.2) | 0/4 (0.0) | 2/15 (13.3) | 15/18 (83.3) | 17/33 (51.5) |
*Values are no./no. (%). Denominators exclude case-patients where information on the symptom was unknown or not collected. ND, no data were available.
1Members of this group are listed at the end of this article.
Page created: March 12, 2025
Page updated: April 28, 2025
Page reviewed: April 28, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.